Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/BIRC6_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BIRC6_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BIRC6_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/BIRC6_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BIRC6_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/BIRC6_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BIRC6_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/BIRC6_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BIRC6_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BIRC6_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BIRC6_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BIRC6_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00109518 | Lung | IAC | negative regulation of endopeptidase activity | 41/2061 | 252/18723 | 6.84e-03 | 4.75e-02 | 41 |
GO:200123313 | Lung | AIS | regulation of apoptotic signaling pathway | 71/1849 | 356/18723 | 6.10e-09 | 9.87e-07 | 71 |
GO:200123413 | Lung | AIS | negative regulation of apoptotic signaling pathway | 46/1849 | 224/18723 | 1.19e-06 | 8.00e-05 | 46 |
GO:006145812 | Lung | AIS | reproductive system development | 70/1849 | 427/18723 | 1.52e-05 | 5.50e-04 | 70 |
GO:004860811 | Lung | AIS | reproductive structure development | 69/1849 | 424/18723 | 2.23e-05 | 7.42e-04 | 69 |
GO:009719113 | Lung | AIS | extrinsic apoptotic signaling pathway | 41/1849 | 219/18723 | 4.46e-05 | 1.33e-03 | 41 |
GO:200123613 | Lung | AIS | regulation of extrinsic apoptotic signaling pathway | 31/1849 | 151/18723 | 6.27e-05 | 1.70e-03 | 31 |
GO:000170112 | Lung | AIS | in utero embryonic development | 59/1849 | 367/18723 | 1.20e-04 | 2.75e-03 | 59 |
GO:200123713 | Lung | AIS | negative regulation of extrinsic apoptotic signaling pathway | 22/1849 | 97/18723 | 1.58e-04 | 3.34e-03 | 22 |
GO:004586113 | Lung | AIS | negative regulation of proteolysis | 55/1849 | 351/18723 | 3.87e-04 | 6.72e-03 | 55 |
GO:005254713 | Lung | AIS | regulation of peptidase activity | 68/1849 | 461/18723 | 5.01e-04 | 8.23e-03 | 68 |
GO:000189212 | Lung | AIS | embryonic placenta development | 18/1849 | 82/18723 | 9.09e-04 | 1.21e-02 | 18 |
GO:005254813 | Lung | AIS | regulation of endopeptidase activity | 63/1849 | 432/18723 | 1.06e-03 | 1.38e-02 | 63 |
GO:000189012 | Lung | AIS | placenta development | 25/1849 | 144/18723 | 3.71e-03 | 3.47e-02 | 25 |
GO:200123323 | Lung | AAH | regulation of apoptotic signaling pathway | 28/613 | 356/18723 | 1.86e-05 | 3.42e-03 | 28 |
GO:000170121 | Lung | AAH | in utero embryonic development | 24/613 | 367/18723 | 1.09e-03 | 3.25e-02 | 24 |
GO:200123423 | Lung | AAH | negative regulation of apoptotic signaling pathway | 17/613 | 224/18723 | 1.17e-03 | 3.33e-02 | 17 |
GO:006145821 | Lung | AAH | reproductive system development | 26/613 | 427/18723 | 1.90e-03 | 4.35e-02 | 26 |
GO:200123333 | Lung | MIAC | regulation of apoptotic signaling pathway | 38/967 | 356/18723 | 1.88e-05 | 1.27e-03 | 38 |
GO:200123432 | Lung | MIAC | negative regulation of apoptotic signaling pathway | 25/967 | 224/18723 | 2.45e-04 | 8.13e-03 | 25 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa042156 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0421511 | Esophagus | ESCC | Apoptosis - multiple species | 25/4205 | 32/8465 | 9.13e-04 | 2.92e-03 | 1.49e-03 | 25 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BIRC6 | SNV | Missense_Mutation | | c.10511N>A | p.Ser3504Asn | p.S3504N | Q9NR09 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0D0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
BIRC6 | SNV | Missense_Mutation | | c.11476N>G | p.Leu3826Val | p.L3826V | Q9NR09 | protein_coding | tolerated(0.63) | benign(0.29) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
BIRC6 | SNV | Missense_Mutation | | c.13787G>T | p.Ser4596Ile | p.S4596I | Q9NR09 | protein_coding | deleterious(0) | possibly_damaging(0.863) | TCGA-A7-A13F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
BIRC6 | SNV | Missense_Mutation | | c.13846C>A | p.Pro4616Thr | p.P4616T | Q9NR09 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
BIRC6 | SNV | Missense_Mutation | rs769761198 | c.4802C>T | p.Thr1601Ile | p.T1601I | Q9NR09 | protein_coding | tolerated(0.1) | possibly_damaging(0.791) | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
BIRC6 | SNV | Missense_Mutation | | c.8318N>A | p.Gly2773Glu | p.G2773E | Q9NR09 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BIRC6 | SNV | Missense_Mutation | | c.12614N>T | p.Ser4205Leu | p.S4205L | Q9NR09 | protein_coding | tolerated(1) | benign(0.12) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BIRC6 | SNV | Missense_Mutation | | c.13264N>A | p.Glu4422Lys | p.E4422K | Q9NR09 | protein_coding | tolerated(0.08) | probably_damaging(0.92) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BIRC6 | SNV | Missense_Mutation | novel | c.9733N>T | p.Ala3245Ser | p.A3245S | Q9NR09 | protein_coding | tolerated(0.52) | benign(0.007) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
BIRC6 | SNV | Missense_Mutation | novel | c.6674N>T | p.Arg2225Ile | p.R2225I | Q9NR09 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |